share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Apr 10 04:05
Summary by Futu AI
Clearmind Medicine Inc., a clinical-stage biotech company, has issued a letter to shareholders on April 9, 2024, outlining significant progress in its research and development efforts, particularly with its flagship compound CMND-100. The CEO, Dr. Adi Zuloff-Shani, highlighted the company's advancements in treating alcohol use disorder (AUD) and other mental health conditions. Clearmind has received approval from the Israeli Ministry of Health for a Phase I/IIa clinical trial for CMND-100, which has shown promising results in pre-clinical studies without inducing hallucinations. The company has completed a Type A meeting with the FDA, formed a Data and Safety Monitoring Board, secured IRB Approval in Israel, and announced U.S. clinical trial sites at Johns Hopkins University and Yale...Show More
Clearmind Medicine Inc., a clinical-stage biotech company, has issued a letter to shareholders on April 9, 2024, outlining significant progress in its research and development efforts, particularly with its flagship compound CMND-100. The CEO, Dr. Adi Zuloff-Shani, highlighted the company's advancements in treating alcohol use disorder (AUD) and other mental health conditions. Clearmind has received approval from the Israeli Ministry of Health for a Phase I/IIa clinical trial for CMND-100, which has shown promising results in pre-clinical studies without inducing hallucinations. The company has completed a Type A meeting with the FDA, formed a Data and Safety Monitoring Board, secured IRB Approval in Israel, and announced U.S. clinical trial sites at Johns Hopkins University and Yale School of Medicine. Clearmind also reported progress in obesity and metabolic disorders research, a collaboration with CTS Ltd., and the expansion of its patent portfolio. Looking forward, Clearmind anticipates initiating the Phase I/IIa trial for AUD, expanding strategic alliances, advancing obesity research, and progressing its MEAI-based alcohol substitute for the consumer market. The company's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY0' respectively.

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.